This study is testing a medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn’s Disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.

This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat Crohn's disease (CD). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating CD.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active CD.

This study is testing an investigational medicine called afimkibart. Afimkibart is an investigational medicine being developed to treat ulcerative colitis (UC). This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for treating UC.  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is. This is compared to a placebo in people living with moderately to severely active UC.

This study is testing an investigational medicine called afimkibart.  Afimkibart is an investigational medicine being developed to treat ulcerative colitis (UC)  This study aims to compare the effects of afimkibart as long-term treatment against ‘placebo’. A placebo is a medicine that contains no active ingredients but looks the same as the study medicine. Researchers want to see if afimkibart works, how well it works and how safe it is when given over a long period of time. This is compared to a placebo in people living with moderately to severely active UC.

The study objective is to assess the efficacy, safety, and pharmacokinetics of an investigational drug in pediatric subjects from 2 to < 18 years of age with moderately to severely active Crohn’s disease (CD) who have had inadequate responses, loss of response, or intolerance to corticosteroids, immunosuppressants, and/or biologics, or in whom use of those therapies is medically contraindicated.

The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of investigational      drug in inducing and maintaining clinical remission in pediatric patients 2 to 17 years of age with moderately   to severely active UC, who have had an inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy.

The objective of this study is to assess the PK, efficacy, and safety of the investigational drug in pediatric patients with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to aminosalicylates, oral locally acting corticosteroids, systemic corticosteroids, immunosuppressants, and/or biologic therapies.

The purpose of the FUZION Study is to evaluate the efficacy and safety of the investigational study medication in participants with Fistulizing, Perianal Crohn’s Disease

Patients who completed the induction treatment of 8 weeks can roll over into a subsequent maintenance study with the objective to evaluate long-term safety and efficacy of obefazimod (ABX464). The maintenance trial consists of a 44-weeks treatment period followed by a 4-weeks follow-up period.

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system in adults. In this study, children and teenagers with moderate to severe Crohn’s Disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after study treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.